-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Not long ago, the sixth batch of insulin special collection has officially "boots", and the tens of billions market is about to be leveraged
.
Now, the seventh batch of national talents is also ready to come out
.
Based on the rules and experience of previous rounds of national procurement, the industry estimates that the seventh batch of national procurement may begin in early 2022
.
So, which varieties will be included in the seventh batch of national sources? Although there is no definitive list released, according to the general speculation in the industry, the variety of injections may be "the highlight
.
" At present, among the injections not included in the national procurement, 50 varieties have met the competition conditions of 3 or more (3 over-evaluated or 2 over-evaluated + 1 original research).
The total sales scale of China's public medical institutions in 2020 Over 60 billion yuan, 22 of which have sales of more than 1 billion yuan.
Piperacillin and tazobactam injection, meropenem injection, and omeprazole injection have annual sales of more than 5 billion yuan
.
In the field of anti-tumor drugs, as of now, 10 varieties have met the national centralized procurement requirements, including afatinib oral regular-release dosage form, erlotinib oral regular-release dosage form, lenvatinib oral regular-release dosage form, and irinote Kang injection, sunitinib oral regular-release dosage form, temozolomide injection, nedaplatin injection, dasatinib oral regular-release dosage form, vinorelbine injection, trifluridine oral tepipyrimidine oral regular-release dosage form
.
In 2020, the total terminal sales of these 10 generic drugs involved in public medical institutions in China will exceed 4.
4 billion yuan
.
Among the 10 varieties of anti-tumor drug injections that meet the requirements, many companies have over-rated 3 companies, and it is expected that the competition in national procurement will be very fierce
.
For example, there are 7 companies that have reviewed afatinib oral regular-release dosage forms, namely CSPC, Kelun Pharmaceutical, Hausen Pharmaceutical, Chia Tai Tianqing, Qilu Pharmaceutical, Yangzijiang Pharmaceutical, and Shanxiang Pharmaceutical
.
Relevant statistics show that the sales of this product in China's public medical institutions in 2020 will be 435 million yuan
.
There are 6 companies that have reviewed erlotinib's oral regular-release dosage form, including Kelun Pharmaceutical, Xinlitai, Hausen Pharmaceutical, Terui Pharmaceutical, Youke Pharmaceutical, and Chuangnuo Pharmaceutical
.
According to relevant statistics, the terminal sales of this product in China's public medical institutions will be 245 million yuan in 2020.
.
For another example, lenvatinib oral dosage form and irinotecan injection have been reviewed by 5 companies, of which irinotecan injection is also a large variety with sales of over 1 billion yuan
.
Data show that the terminal sales of this product in China's public medical institutions will be 1.
712 billion yuan in 2020
.
In addition, from the perspective of these 10 companies with a large number of products, Qilu Pharmaceutical has a large number of products, with a total of 7 products reviewed; Chia Tai Tianqing has 5 products reviewed; Hausen Pharmaceuticals has 4 products reviewed; in addition, , Kelun Pharmaceutical and CSPC Group each have 3 products reviewed
.
In terms of the current situation of centralized drug procurement, 44 injections have been included in the first five rounds of centralized procurement, and the number of injections is increasing
.
Among them, the fifth batch of countries adopted 30 injection varieties, accounting for more than half, which is greater than the sum of the previous purchases with volume, and the amount involved accounts for about 70% of the total amount of the fifth batch of centralized procurement
.
With the increase in the number of over-evaluated injections, the industry predicts that the number of injections in the seventh batch of national centralized procurement is expected to reach a new high
.
Coupled with the advancement of local centralized procurement and alliance centralized procurement, the 100 billion injection market will continue to reshuffle
.
.
Now, the seventh batch of national talents is also ready to come out
.
Based on the rules and experience of previous rounds of national procurement, the industry estimates that the seventh batch of national procurement may begin in early 2022
.
So, which varieties will be included in the seventh batch of national sources? Although there is no definitive list released, according to the general speculation in the industry, the variety of injections may be "the highlight
.
" At present, among the injections not included in the national procurement, 50 varieties have met the competition conditions of 3 or more (3 over-evaluated or 2 over-evaluated + 1 original research).
The total sales scale of China's public medical institutions in 2020 Over 60 billion yuan, 22 of which have sales of more than 1 billion yuan.
Piperacillin and tazobactam injection, meropenem injection, and omeprazole injection have annual sales of more than 5 billion yuan
.
In the field of anti-tumor drugs, as of now, 10 varieties have met the national centralized procurement requirements, including afatinib oral regular-release dosage form, erlotinib oral regular-release dosage form, lenvatinib oral regular-release dosage form, and irinote Kang injection, sunitinib oral regular-release dosage form, temozolomide injection, nedaplatin injection, dasatinib oral regular-release dosage form, vinorelbine injection, trifluridine oral tepipyrimidine oral regular-release dosage form
.
In 2020, the total terminal sales of these 10 generic drugs involved in public medical institutions in China will exceed 4.
4 billion yuan
.
Among the 10 varieties of anti-tumor drug injections that meet the requirements, many companies have over-rated 3 companies, and it is expected that the competition in national procurement will be very fierce
.
For example, there are 7 companies that have reviewed afatinib oral regular-release dosage forms, namely CSPC, Kelun Pharmaceutical, Hausen Pharmaceutical, Chia Tai Tianqing, Qilu Pharmaceutical, Yangzijiang Pharmaceutical, and Shanxiang Pharmaceutical
.
Relevant statistics show that the sales of this product in China's public medical institutions in 2020 will be 435 million yuan
.
There are 6 companies that have reviewed erlotinib's oral regular-release dosage form, including Kelun Pharmaceutical, Xinlitai, Hausen Pharmaceutical, Terui Pharmaceutical, Youke Pharmaceutical, and Chuangnuo Pharmaceutical
.
According to relevant statistics, the terminal sales of this product in China's public medical institutions will be 245 million yuan in 2020.
.
For another example, lenvatinib oral dosage form and irinotecan injection have been reviewed by 5 companies, of which irinotecan injection is also a large variety with sales of over 1 billion yuan
.
Data show that the terminal sales of this product in China's public medical institutions will be 1.
712 billion yuan in 2020
.
In addition, from the perspective of these 10 companies with a large number of products, Qilu Pharmaceutical has a large number of products, with a total of 7 products reviewed; Chia Tai Tianqing has 5 products reviewed; Hausen Pharmaceuticals has 4 products reviewed; in addition, , Kelun Pharmaceutical and CSPC Group each have 3 products reviewed
.
In terms of the current situation of centralized drug procurement, 44 injections have been included in the first five rounds of centralized procurement, and the number of injections is increasing
.
Among them, the fifth batch of countries adopted 30 injection varieties, accounting for more than half, which is greater than the sum of the previous purchases with volume, and the amount involved accounts for about 70% of the total amount of the fifth batch of centralized procurement
.
With the increase in the number of over-evaluated injections, the industry predicts that the number of injections in the seventh batch of national centralized procurement is expected to reach a new high
.
Coupled with the advancement of local centralized procurement and alliance centralized procurement, the 100 billion injection market will continue to reshuffle
.
